However, AMD3100 is reported to display a weak partial agonist activity35, 36, inducing CXCL12-like G-protein activation in CXCR4-expression cells upon binding of it, which could be a disadvantage to the treatment of leukemia, because CXCR4 activation provides a survival signal for leukemia cells. Here, CXCR4 is linked to leukemia.